Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | C1S | P09871 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | DHFR | P00374 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9312087 | 0.85 | KCNH2 (0.46) | DPP4ADRB1KCNH2C1SMAPT | |
| SCHEMBL9310734 | 0.84 | ADRB1 (0.50) | DPP4ADRB1KCNH2C1SMAPT | |
| SCHEMBL9312192 | 0.84 | KCNH2 (0.53) | DPP4ADRB1KCNH2C1SMAPT | |
| SCHEMBL9309910 | 0.83 | RAB9A (0.50) | DPP4ADRB1KCNH2C1SMAPT | |
| SCHEMBL9312009 | 0.82 | MAPT (0.49) | DPP4ADRB1KCNH2C1SMAPT | |
| SCHEMBL9310603 | 0.82 | KCNH2 (0.47) | DPP4ADRB1KCNH2MAPTALDH1A1 | |
| SCHEMBL9310193 | 0.81 | ADRB1 (0.50) | DPP4ADRB1KCNH2C1SMAPT | |
| SCHEMBL9311673 | 0.81 | ADRB1 (0.50) | DPP4ADRB1KCNH2C1SMAPT | |
| SCHEMBL9312010 | 0.81 | ADRB1 (0.50) | DPP4ADRB1KCNH2C1SMAPT | |
| SCHEMBL5089006 | 0.81 | CYP1A2 (0.53) | ADRB1KCNH2C1SMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4956351-A | INCLUSION COMPLEXESOFVIRICIDES; RHINITIS; SUSTAINED RELEASE; NONIRRITATING TO MUCOUS MEMBRANE | JANSSEN PHARMACEUTICA N.V. FRAME-543 (BE) | 1990-09-11 | — | — | US | claimed |
| EP-0300526-A2 | Antiviral pharmaceutical compositions containing cyclodextrins | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-25 | — | — | EP | claimed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| EP-1804799-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | disclosed |
| US-8026360-B2 | Substituted pyridazines as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| EP-2269610-A2 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2011-01-05 | — | — | EP | disclosed |
| EP-0156433-B1 | ANTI-VIRALLY ACTIVE PYRIDAZINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-27 | — | — | EP | disclosed |
| US-4956351-A | INCLUSION COMPLEXESOFVIRICIDES; RHINITIS; SUSTAINED RELEASE; NONIRRITATING TO MUCOUS MEMBRANE | JANSSEN PHARMACEUTICA N.V. FRAME-543 (BE) | 1990-09-11 | — | — | US | disclosed |
| US-4870060-A | SOLUBILIZERS FOR DRUGS | JANSSEN PHARMACEUTICA (BE) | 1989-09-26 | — | — | US | disclosed |
| US-4837168-A | QUALITATIVE, QUANTITATIVE ANALYSIS; VISUAL DETERMINATION | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-06-06 | — | — | US | disclosed |
| EP-0300526-A2 | Antiviral pharmaceutical compositions containing cyclodextrins | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-25 | — | — | EP | disclosed |
| EP-0293947-A1 | Method for depositing metal particles on a marker | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-12-07 | — | — | EP | disclosed |
| US-4764604-A | Derivatives of gamma-cyclodextrin | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-16 | — | — | US | disclosed |
| EP-0197571-A2 | Novel derivatives of gamma-cyclodextrin | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-15 | — | — | EP | disclosed |
| EP-0156433-A2 | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | DPP4 174/4885ADRB1 114/4885KCNH2 4408/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | DPP4 174/4885ADRB1 114/4885KCNH2 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.